Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subject: EARNINGS

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results


KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors today provided an operational update and released financial results for the fiscal year ended April 30, 2020.

"We have two oral candidates in clinical trials that have the potential to provide HAE patients with a complete set of options to treat their disease," said Andrew Crockett, Chief Executive Officer of KalVista. "We are pleased with our progress with the formulation work for KVD824 to deliver a twice-daily treatment for prevention of HAE attacks. Subjects have begun dosing with these new formulations to obtain additional pharmacokinetic and pharmacodynamic data, and we look forward to providing these data later this year in advance of starting a Phase 2 clinical trial. Patients also continue to be treated in our Phase 2 clinical trial for KVD900 as an on-demand therapy, and we expect data from that trial in the second half of this year."

Fiscal 2020 and Recent Business Highlights:

Fourth Quarter and Full Year Financial Results:

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body's inflammatory response and which, in excess, can lead to increased vascular permeability, edema and inflammation. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company has created a structurally diverse portfolio of oral plasma kallikrein inhibitors and is advancing multiple drug candidates for HAE as well as DME. KalVista has selected KVD900 as its program to be advanced as an on-demand therapy for acute HAE attacks and is conducting a Phase 2 proof-of-concept study in HAE patients with data expected in the second half of 2020. KVD824 is in development for prophylactic treatment of HAE and is expected to enter a Phase 2 clinical trial in the second half of 2020. In DME, an intravitreally administered plasma kallikrein inhibitor known as KVD001, completed a Phase 2 clinical trial in 2019.

For more information, please visit www.kalvista.com.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, available funding, our cash runway, potential future clinical trial timing and results, potential benefits of our product candidates, and the impact of COVID-19. Further information on potential risk factors that could affect our business and its financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2020 once filed, and our other reports that we may file from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

KalVista Pharmaceuticals Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
(Unaudited)
 

April 30,

April 30,

2020

2019

Assets
Current assets:
Cash and cash equivalents

$ 15,789

$ 32,006

Marketable securities

51,925

68,805

Research and development tax credit receivable

16,527

11,315

Prepaid expenses and other current assets

4,455

3,420

Total current assets

88,696

115,546

Property and equipment, net

2,043

2,413

Right of use assets

1,612

?
Other assets

178

173

Total assets

$ 92,529

$ 118,132

Liabilities and stockholders' equity
Current liabilities:
Accounts payable

$ 1,677

$ 2,860

Accrued expenses

5,455

5,647

Deferred revenue - current portion ?

9,545

Lease liability - current portion

588

?
Total current liabilities

7,720

18,052

Long-term liabilities:
Deferred revenue - net of current portion ?

3,342

Lease liability - net of current portion

1,057

?
Total long-term liabilities

1,057

3,342

Stockholders' equity:
Common stock, $0.001 par value

18

17

Additional paid-in capital

207,208

191,123

Accumulated deficit

(121,592)

(92,476)

Accumulated other comprehensive loss

(1,882)

(1,926)

Total stockholders' equity

83,752

96,738

Total liabilities and stockholders' equity

$ 92,529

$ 118,132

KalVista Pharmaceuticals Inc.
Condensed Consolidated Statement of Operations
(in thousands, except share and per share amounts)
(Unaudited)
 
 
Three Months Ended Years Ended
April 30, April 30,

2020

2019

2020

2019

 
Revenue

$ 3,824

$ 2,926

$ 12,690

$ 16,127

Operating expenses:
Research and development

9,485

11,139

40,194

35,021

General and administrative

3,296

3,047

13,029

10,926

Total operating expenses

12,781

14,186

53,223

45,947

Operating loss

(8,957)

(11,260)

(40,533)

(29,820)

 
Other income:
Interest income

363

381

1,830

1,397

Foreign currency exchange rate gain (loss)

(613)

(34)

(367)

49

Other income

2,498

2,511

9,830

7,682

Total other income

2,248

2,858

11,293

9,128

Loss before income taxes

(6,709)

(8,402)

(29,240)

(20,692)

Income tax (benefit) expense

(124)

124

(124)

124

Net loss

$ (6,585)

$ (8,526)

$ (29,116)

$ (20,816)

 
Net loss per share, basic and diluted

$ (0.37)

$ (0.49)

$ (1.64)

$ (1.38)

 
Weighted average common shares outstanding, basic and diluted

17,845,599

17,253,938

17,748,666

15,080,863

KalVista Pharmaceuticals Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands, unaudited)
 
Years Ended
April 30,

2020

2019

 
Cash flows from operating activities
Net loss

$ (29,116)

$ (20,816)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

512

378

Stock-based compensation expense

4,448

2,966

Realized (gain) from marketable securities

(300)

(23)

Non-cash operating lease expense

13

?
Amortization of premium on available for sale securities

193

?
Foreign currency exchange (gain) loss

74

(80)

Changes in operating assets and liabilities:
Research and development tax credit receivable

(5,781)

(4,883)

Prepaid expenses and other current assets

(1,112)

(1,979)

Other assets

(5)

?
Accounts payable

(1,004)

1,534

Accrued expenses

(48)

2,665

Deferred revenue

(12,690)

(16,127)

Net cash used in operating activities

(44,816)

(36,365)

 
Cash flows from investing activities
Purchases of available for sale securities

(49,797)

(79,889)

Sales and maturities of available for sale securities

66,770

11,548

Acquisition of property and equipment

(220)

(1,081)

Net cash provided by (used in) investing activities

16,753

(69,422)

 
Cash flows from financing activities
Issuance of common stock, net of offering expenses

11,422

87,910

Issuance of common stock from equity incentive plans

216

242

Finance lease principal payments

(54)

(209)

Net cash provided by financing activities

11,584

87,943

Effect of exchange rate changes on cash and cash equivalents

262

(1,205)

Net decrease in cash and cash equivalents

(16,217)

(19,049)

Cash and cash equivalents, beginning of year

32,006

51,055

Cash and cash equivalents, end of year

$ 15,789

$ 32,006

 


These press releases may also interest you

at 20:44
Health Vector, an innovative health information management company, announced the appointment of Joshua Heapes as the company's Chief Growth Officer. In this role, Mr. Heapes will lead the expansion of Health Vector's commercial organization...

at 20:05
Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today the completion of study subjects enrollment in Phase I trial of...

at 19:10
Churchill Capital Corp III ("Churchill") , a public investment vehicle, and MultiPlan, Inc. ("MultiPlan"), a market-leading, technology-enabled provider of end-to-end healthcare cost management solutions, announced today that they have entered into a...

at 13:42
Health Vector recently partnered with a major healthcare system to garner the power of AI to support medical documentation. The new product, Health Vector Clinical Transcriptions, demonstrates how instant transcription of medical encounters helps...

at 12:37
Essity's Half-year Report for 2020 will be published on Monday, July 13 at approximately 7:00 a.m. CET instead of Friday, July 17 as previously communicated. The reason for the earlier publishing date is the uncertainty entailed by the ongoing...

at 12:00
In lieu of an in-person update to the media, Dr. Howard Njoo, Canada's Deputy Chief Public Health Officer, issued the following statement on behalf of Dr. Theresa Tam, Canada's Chief Public Health Officer. "There have been 107,347 cases of COVID-19...



News published on 1 july 2020 at 07:05 and distributed by: